Prime Medicine, Valuation
| PRME Etf | USD 1.95 0.06 2.99% |
Based on Macroaxis valuation methodology, the etf appears to be fairly valued. Prime Medicine, Common holds a recent Real Value of $1.92 per share. The prevailing price of the etf is $1.95. Our model determines the value of Prime Medicine, Common from analyzing the etf fundamentals such as Return On Equity of -1.37, current valuation of 105.46 M, and Shares Owned By Insiders of 23.90 % as well as examining its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that Prime Medicine,'s price fluctuation is dangerous at this time. Calculation of the real value of Prime Medicine, Common is based on 3 months time horizon. Increasing Prime Medicine,'s time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Prime etf is determined by what a typical buyer is willing to pay for full or partial control of Prime Medicine, Common. Since Prime Medicine, is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Prime Etf. However, Prime Medicine,'s intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.95 | Real 1.92 | Hype 1.95 | Naive 2.11 |
The real value of Prime Etf, also known as its intrinsic value, is the underlying worth of Prime Medicine, Common ETF, which is reflected in its stock price. It is based on Prime Medicine,'s financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Prime Medicine,'s stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Prime Medicine, Common helps investors to forecast how Prime etf's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Prime Medicine, more accurately as focusing exclusively on Prime Medicine,'s fundamentals will not take into account other important factors: Prime Medicine, Total Value Analysis
Prime Medicine, Common is at this time expected to have valuation of 105.46 M with market capitalization of 255.76 M, debt of 40.79 M, and cash on hands of 146.66 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Prime Medicine, fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
105.46 M | 255.76 M | 40.79 M | 146.66 M |
Prime Medicine, Investor Information
The fund maintains 99.55% of assets in stocks. Based on the key measurements obtained from Prime Medicine,'s financial statements, Prime Medicine, Common is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Prime Medicine, Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Prime Medicine, has an asset utilization ratio of 1.0 percent. This indicates that the ETF is making $0.01 for each dollar of assets. An increasing asset utilization means that Prime Medicine, Common is more efficient with each dollar of assets it utilizes for everyday operations.Prime Medicine, Ownership Allocation
Prime Medicine, owns a total of 131.16 Million outstanding shares. Over half of Prime Medicine,'s outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the etf is less than the current market value, you may not be able to make money on it.Prime Medicine, Profitability Analysis
The company reported the previous year's revenue of 2.98 M. Net Loss for the year was (195.88 M) with loss before overhead, payroll, taxes, and interest of (152.31 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Prime Medicine,'s worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Prime Medicine, and how it compares across the competition.
About Prime Medicine, Valuation
The etf valuation mechanism determines Prime Medicine,'s current worth on a weekly basis. Our valuation model uses a comparative analysis of Prime Medicine,. We calculate exposure to Prime Medicine,'s market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Prime Medicine,'s related companies.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. Prime Medicine is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange.
Prime Medicine, Growth Indicators
Investing in growth stocks can be very risky. If the company such as Prime Medicine, does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 118.6 M |
Other Information on Investing in Prime Etf
Prime Medicine, financial ratios help investors to determine whether Prime Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Prime with respect to the benefits of owning Prime Medicine, security.